Loading organizations...

§ Private Profile · Alameda, CA, USA
Santa Ana Bio is a technology company.
Santa Ana Bio is a precision immunology company developing targeted therapies. It leverages multi-omics platforms and antibody engineering to design precision biologics. The company’s technical approach uses deep cell profiling to understand and address disease mechanisms, creating highly specific treatments for complex conditions.
The company emerged from stealth after a period of focused development. While specific founders are not detailed, the organization is led by a former Kite executive, bringing strong therapeutic innovation pedigree. The central insight driving Santa Ana Bio is applying precision medicine, empowered by multi-omic profiling, to autoimmune and inflammatory diseases.
Santa Ana Bio directs therapeutic development towards patients with autoimmune and inflammatory diseases. The company’s long-term vision is to advance its precision biologics through clinical development, delivering novel, targeted medicines to improve patient outcomes by precisely addressing molecular disease drivers.
Santa Ana Bio has raised $173.0M across 2 funding rounds.
Santa Ana Bio has raised $173.0M in total across 2 funding rounds.
Santa Ana Bio has raised $173.0M across 2 funding rounds. Most recently, it raised $130.0M Series B in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2024 | $130M Series B | GV, Versant Ventures | Access Biotechnology, Andreessen Horowitz, James Hardiman, Hummingbird Ventures, M34 Capital, Remus Capital, Johannes Schildt, Shinichiro Fuse | Announced |
| Feb 1, 2023 | $43M Series A | — | Access Biotechnology, Andreessen Horowitz, Brendan Bulik Sullivan, GV, MPM Capital, Taiho Ventures, Versant Ventures, Shinichiro Fuse | Announced |
Santa Ana Bio is a precision immunology biotechnology company headquartered in Alameda, California, focused on developing targeted therapies for patients with autoimmune and inflammatory diseases.[1][2][4] It leverages multi-omics platforms (transcriptomics and proteomics) and antibody engineering to create innovative therapeutics that address limitations of current treatments by targeting causal cells and pathways more precisely.[2][3][4] Founded in 2022, the company emerged from stealth with $168 million in Series A and B funding from investors including Versant Ventures, GV, TPG’s Life Science Innovations, Access Biotechnology, Andreessen Horowitz Bio + Health, and RTW.[2] It has advanced three programs poised for clinical entry, including SAB05 (antibody-glucocorticoid conjugate) and others offering improvements over competing molecules, serving patients underserved by existing therapies.[2][6]
Santa Ana Bio was founded in 2022 by Peter Emtage, who serves as CEO, with co-founder and CTO Danny Wells, drawing on expertise in protein sciences, immunology, and drug development.[1][2][5] The company emerged from stealth that same year, rapidly advancing a pipeline while benefiting from leading academic founders and advisors.[2] Backed by Versant Ventures as the lead Series A investor, it secured $168 million in funding to fuel its multi-omics platform for precision medicines in immunology.[2] Early momentum included quick progression of three programs toward the clinic, highlighting pivotal execution since inception.[2]
Santa Ana Bio rides the wave of precision immunology and multi-omics in biotech, targeting the growing autoimmune disease market where current therapies fall short for many patients.[2][5] Timing aligns with advances in single-cell profiling and antibody-drug conjugates (ADCs), enabling therapies that minimize off-target effects like those from traditional glucocorticoids.[2][6] Favorable market forces include surging demand for biologics in immunology (e.g., monoclonal antibodies) and investor enthusiasm for platforms unlocking new pathways, as seen in its $168 million raise from elite VCs.[2] The company influences the ecosystem by pushing precision approaches to diverse cell types, potentially reshaping treatments for high-unmet-need diseases and accelerating clinical benchmarks.[2][6]
Santa Ana Bio is primed for clinical milestones, with SAB01 entering Phase 1 in mid-2026, SAB05 advancing through IND studies, and SAB03/SAB06 nearing development candidate status.[6] Trends like AI-enhanced multi-omics and next-gen ADCs will amplify its platform, positioning it to capture share in the expanding autoimmune biologics market.[2][5][6] Under new Board Chair Mike Bonney, expect scaled operations, potential partnerships, and further funding to broaden its immunology footprint, evolving from stealth innovator to pipeline leader delivering patient impact.[6] This momentum underscores its potential to redefine precision medicines from the outset.
Santa Ana Bio has raised $173.0M in total across 2 funding rounds.
Santa Ana Bio's investors include GV, Versant Ventures, Access Biotechnology, Andreessen Horowitz, James Hardiman, Hummingbird Ventures, M34 Capital, REMUS Capital, Johannes Schildt, Shinichiro Fuse, Brendan Bulik-Sullivan, MPM Capital.